Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
This study is testing a personalized approach to cancer treatment using "smart" drugs called antibody-drug conjugates (ADCs). These drugs act like guided missiles, attaching directly to specific proteins on cancer cells to deliver medicine while sparing healthy cells.
This trial is for people with advanced solid tumors that have stopped responding to standard treatments. To join, your tumor will be tested to see if it carries the specific proteins—Trop-2, nectin-4, or HER2—that these targeted drugs are designed to attack.
After a biopsy confirms the proteins in your tumor, you will receive one of the study drugs matched to your specific cancer type. You will also have regular check-ups, including heart function tests and medical scans, to monitor your safety and how well the treatment is working.
The study is currently recruiting patients at specific locations in California, including Duarte, Encinitas, and Irvine. Please speak with your doctor or the trial team to see if one of these centers is an option for you.
- 1Uses precision medicine to match a specific drug to your tumor's unique makeup.
- 2Designed for patients whose cancer has progressed after standard treatment options.
- 3Includes regular monitoring, such as heart scans and imaging, to ensure your health and safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.